

Amgen Raises EPOGEN Pricing

TORRANCE, Calif., Feb. 25 /PRNewswire/ -- Total Renal Care Holdings, Inc. (NYSE: TRL), the nation's second-largest provider of dialysis services, announced that today it received notice from Amgen Inc. that as of February 24, 2000 at 5:01 p.m. Pacific Time, Amgen Inc. will increase their Wholesaler Acquisition Price for EPOGEN by approximately 3.9%. Without any changes to our current contractual arrangements with Amgen, this price increase would have a negative impact on our remaining ten-month after-tax earnings for 2000 of \$0.055 to \$0.065.

Total Renal Care Holdings, Inc., based in Torrance, California, is the nation's second-largest provider of dialysis services for patients suffering from chronic kidney failure. The Company owns and operates kidney dialysis centers and home peritoneal dialysis programs domestically in 32 states, as well as Washington, D.C. It also provides acute hemodialysis services to inpatients at approximately 330 hospitals. As of December 1, 1999, Total Renal Care operated 488 outpatient dialysis facilities serving over 40,000 patients, including 3,700 patients in 49 centers under management.

SOURCE Total Renal Care Holdings, Inc.

CONTACT: LeAnne Zumwalt, Investor Relations of Total Renal Care, Inc., 310-792-2600, ext. 2449/

<https://davita.mediaroom.com/press-releases?item=123051>